Literature DB >> 19416945

Influence of age at disease onset in the outcome of paediatric systemic lupus erythematosus.

Elodie Descloux1, Isabelle Durieu, Pierre Cochat, Denis Vital-Durand, Jacques Ninet, Nicole Fabien, Rolando Cimaz.   

Abstract

OBJECTIVES: The aim of this study was to investigate the influence of age at disease onset in the outcome of paediatric SLE (pSLE).
METHODS: Fifty-six patients with pSLE, divided into three groups (pre-pubertal, peripubertal and post-pubertal onset), were studied. The SDI (SLICC/ACR Damage Index for SLE), patients' characteristics, disease manifestations and treatments were compared using Fisher's exact test and Kruskal-Wallis test. Kaplan-Meier curves were constructed to compare the risk of damage occurrence.
RESULTS: The risk of damage (SDI >or=1) significantly decreased when age at disease onset increased (89% in pre-pubertal pSLE, 57% in peripubertal pSLE and 38% in post-pubertal pSLE). This excess of risk was found in all disease duration intervals studied (1-3, 3-5, 5-8, 8-10, >10 years) and at the end of follow-up. Kaplan-Meier curves indicated a higher and earlier risk of damage in younger patients. Young children showed higher frequency of autoimmune family history. The frequency of neuropsychiatric disorders and damages decreased with age at disease onset (P < 0.05). Cumulative duration of high-dose prednisone (> 0.5 mg/kg/day) and number of immunosuppressive drugs used that seem to contribute to damage significantly increased when age at disease onset decreased.
CONCLUSIONS: The risk of damage is inversely correlated with age at disease onset in pSLE. The poorer outcome observed in younger children may be explained by a more severe disease expression, may be a higher infectious susceptibility, and a more aggressive therapy, particularly within the first 6 months of disease course.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19416945     DOI: 10.1093/rheumatology/kep067

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  19 in total

1.  Population-level evidence for an autoimmune etiology of epilepsy.

Authors:  Mei-Sing Ong; Isaac S Kohane; Tianxi Cai; Mark P Gorman; Kenneth D Mandl
Journal:  JAMA Neurol       Date:  2014-05       Impact factor: 18.302

2.  Dissecting the damage in Northern Greek patients with childhood-onset systemic lupus erythematosus: a retrospective cohort study.

Authors:  Artemis Koutsonikoli; Maria Trachana; Anna-Bettina Heidich; Vasiliki Galanopoulou; Polyxeni Pratsidou-Gertsi; Alexandros Garyphallos
Journal:  Rheumatol Int       Date:  2015-01-14       Impact factor: 2.631

3.  Age of onset influences on clinical and laboratory profile of patients with systemic lupus erythematosus.

Authors:  Rafael Hennemann Sassi; Jordana Vaz Hendler; Giovana Fagundes Piccoli; Andrese Aline Gasparin; Rafael Mendonça da Silva Chakr; João Carlos Tavares Brenol; Odirlei André Monticielo
Journal:  Clin Rheumatol       Date:  2016-11-17       Impact factor: 2.980

4.  Inpatient health care utilization by children and adolescents with systemic lupus erythematosus and kidney involvement.

Authors:  Marie Tanzer; Cheryl Tran; Kassandra L Messer; Amber Kroeker; Emily Herreshoff; Larysa Wickman; Courtney Harkness; Peter Song; Debbie S Gipson
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-03       Impact factor: 4.794

5.  Gastrointestinal system manifestations in juvenile systemic lupus erythematosus.

Authors:  Hafize Emine Sönmez; Asuman Nur Karhan; Ezgi Deniz Batu; Yelda Bilginer; Ersin Gümüş; Hülya Demir; Aysel Yüce; Seza Özen
Journal:  Clin Rheumatol       Date:  2017-02-16       Impact factor: 2.980

Review 6.  Tailored treatment strategies and future directions in systemic lupus erythematosus.

Authors:  Dionysis Nikolopoulos; Lampros Fotis; Ourania Gioti; Antonis Fanouriakis
Journal:  Rheumatol Int       Date:  2022-04-21       Impact factor: 3.580

7.  Clinical features and long-term outcomes of systemic lupus erythematosus: comparative data of childhood, adult and late-onset disease in a national register.

Authors:  S Sousa; M J Gonçalves; L S Inês; G Eugénio; D Jesus; S Fernandes; G Terroso; V C Romão; M Cerqueira; A Raposo; M Couto; P Nero; G Sequeira; T Nóvoa; J A Melo Gomes; J Canas da Silva; L Costa; C Macieira; C Silva; J A P Silva; H Canhão; M J Santos
Journal:  Rheumatol Int       Date:  2016-03-15       Impact factor: 2.631

Review 8.  Systemic lupus erythematosus in children and adolescents.

Authors:  Deborah M Levy; Sylvia Kamphuis
Journal:  Pediatr Clin North Am       Date:  2012-04       Impact factor: 3.278

Review 9.  Update on differences between childhood-onset and adult-onset systemic lupus erythematosus.

Authors:  Rina Mina; Hermine I Brunner
Journal:  Arthritis Res Ther       Date:  2013-08-21       Impact factor: 5.156

Review 10.  Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.

Authors:  K D Rainsford; Ann L Parke; Matthew Clifford-Rashotte; W F Kean
Journal:  Inflammopharmacology       Date:  2015-08-06       Impact factor: 5.093

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.